Director/PDMR Shareholding

RNS Number : 9626S

Advanced Medical Solutions Grp PLC

28 June 2018

 

28 June 2018

            Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

            Director/PDMR Shareholding

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces it was notified on 25 June 2018 that Chris Meredith, who is a Director and PDMR, following the end of the holding period, has exercised 27,377 options from the Deferred Annual Bonus Plan (DAB). Chris Meredith elected to receive an additional 347 dividend shares which were earned during the 3 year holding period under the terms of this scheme. Chris Meredith subsequently sold 27,724 Ordinary Shares of 5p each on 25 June 2018 at a share price of 326.50p per Ordinary Share. 

As a result of these transactions Chris Meredith's beneficial interest in the Company remain unchanged.

Deferred Annual Bonus Plan (DAB)

Director	DABs prior to exercise	DABs exercised	Dividend Shares received	Ordinary Shares sold	Ordinary Shares retained	DABs after exercise
Chris Meredith, Chief Executive Officer	105,133	27,377	347	27,724	Nil	77,756

Overall Holding

Director	Holding prior to exercise	Number of shares exercised	Dividend Shares received	Number of shares sold	Sale price (p)	Resultant holding	% of issued share capital
Chris Meredith, Chief Executive Officer	1,484,395	27,377	347	27,724	326.50p	1,484,395	0.7%

The Company further announces that it was notified on 25 June 2018 that Mary Tavener, who is a Director and PDMR, following the end of the holding period, has exercised 19,331 options from the Deferred Annual Bonus Plan (DAB). Mary Tavener elected to receive an additional 245 dividend shares which were earned during the 3 year holding period under the terms of the scheme. Mary Tavener subsequently sold 9,305 Ordinary Shares of 5p each on 25 June 2018 at a share price of 326.50p per Ordinary Share to cover the tax and National Insurance payable on this exercise.  

As a result of these transactions Mary Tavener's beneficial interest in the Company has increased from 1,960,277 shares to 1,970,548 shares.

Deferred Annual Bonus Plan (DAB)

Director	DABs prior to exercise	DABs exercised	Dividend Shares received	Ordinary Shares sold	Ordinary Shares retained	DABs after exercise
Mary Tavener, Chief Financial Officer	69,749	19,331	245	9,305	10,271	50,418

Overall Holding

Director	Holding prior to exercise	Number of shares exercised	Dividend Shares received	Number of shares sold	Number of shares retained	Sale price (p)	Resultant holding	% of issued share capital
Mary Tavener, Chief Financial Officer	1,960,277	19,331	245	9,305	10,271	326.50p	1,970,548	0.92%

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name: Chris Meredith
2.	Reason for the notification
a)	Position/status: Director/PDMR
b)	Initial notification/Amendment: Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name:   Advanced Medical Solutions Group plc
b)	LEI: 213800HJP6OWOSZI1L74
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594
b)	Nature of the transactions: ·        Exercise of 27,377 shares from the Deferred Annual Bonus Plan ·        Award of 347 Dividend Shares from the Deferred Annual Bonus Plan ·        Sale of 27,724 Ordinary Shares of 5p
c)	Price(s) and volume(s): Sale of shares: Price(s) Volume(s) £3.265 27,724
d)	Aggregated information: (Relates to those shares sold only) Aggregated volume: 27,724 Aggregated price: £3.265
e)	Date of the transaction: 25/06/2018
f)	Place of the transaction: London Stock Exchange, AIM Market (XLON)

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name: Mary Tavener
2.	Reason for the notification
a)	Position/status: Director/PDMR
b)	Initial notification/Amendment: Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name:   Advanced Medical Solutions Group plc
b)	LEI: 213800HJP6OWOSZI1L74
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594
b)	Nature of the transactions: ·        Exercise of 19,331 shares from the Deferred Annual Bonus Plan ·        Award of 245 Dividend Shares from the Deferred Annual Bonus Plan ·        Sale of 9,305 Ordinary Shares of 5p
c)	Price(s) and volume(s): Sale of shares: Price(s) Volume(s) £3.265 9,305
d)	Aggregated information: (Relates to those shares sold only) Aggregated volume: 9,305 Aggregated price: £3.265
e)	Date of the transaction: 25/06/2018
f)	Place of the transaction: London Stock Exchange, AIM Market (XLON)

-End -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: [phone]
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer
Consilium Strategic Communications	Tel: [phone]
Mary-Jane Elliott / Matthew Neal / Nicholas Brown	[e-mail]
Investec Bank PLC (NOMAD & Broker)	Tel: [phone]
Daniel Adams / Patrick Robb / Gary Clarence

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Group has approximately 600 employees.  For more information, please see www.admedsol.com.

 

END

 

 

DSHBUGDLDXDBGII